GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (OTCPK:PTCHF) » Definitions » Total Liabilities

PureTech Health (PureTech Health) Total Liabilities : $235.74 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is PureTech Health Total Liabilities?

PureTech Health's Total Liabilities for the quarter that ended in Dec. 2023 was $235.74 Mil.

PureTech Health's quarterly Total Liabilities increased from Dec. 2022 ($155.06 Mil) to Jun. 2023 ($184.66 Mil) and increased from Jun. 2023 ($184.66 Mil) to Dec. 2023 ($235.74 Mil).

PureTech Health's annual Total Liabilities declined from Dec. 2021 ($361.86 Mil) to Dec. 2022 ($155.06 Mil) but then increased from Dec. 2022 ($155.06 Mil) to Dec. 2023 ($235.74 Mil).


PureTech Health Total Liabilities Historical Data

The historical data trend for PureTech Health's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PureTech Health Total Liabilities Chart

PureTech Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 290.78 336.46 361.86 155.06 235.74

PureTech Health Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 361.86 247.13 155.06 184.66 235.74

PureTech Health Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

PureTech Health's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=51.37+(18.25+162.621
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+3.501)
=235.74

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=693.973-458.231
=235.74

PureTech Health's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=51.37+(18.25+162.621
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+3.501)
=235.74

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=693.973-458.231
=235.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PureTech Health Total Liabilities Related Terms

Thank you for viewing the detailed overview of PureTech Health's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


PureTech Health (PureTech Health) Business Description

Traded in Other Exchanges
Address
6 Tide Street, Suite 400, Boston, MA, USA, 02210
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.